Brokers Offer Predictions for Moderna, Inc.’s FY2026 Earnings (NASDAQ:MRNA)
Moderna, Inc. (NASDAQ:MRNA – Free Report) – Stock analysts at Zacks Research issued their FY2026 EPS estimates for shares of Moderna in a note issued to investors on Monday, March 11th. Zacks Research analyst S. Ganoria expects that the company will earn ($1.86) per share for the year. The consensus estimate for Moderna’s current full-year earnings is ($7.27) per share.
Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same period last year, the firm earned $3.61 earnings per share. The business’s revenue for the quarter was down 44.9% on a year-over-year basis.
MRNA has been the subject of several other reports. Canaccord Genuity Group lifted their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Canaccord Genuity Group assumed coverage on shares of Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Friday, February 23rd. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $93.00 to $90.00 and set a “neutral” rating on the stock in a report on Friday, December 1st. Finally, Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $129.82.
Check Out Our Latest Research Report on MRNA
Moderna Price Performance
Shares of NASDAQ:MRNA opened at $110.43 on Tuesday. Moderna has a 52 week low of $62.55 and a 52 week high of $163.24. The firm’s fifty day moving average is $99.20 and its 200-day moving average is $93.82. The firm has a market cap of $42.19 billion, a PE ratio of -8.90 and a beta of 1.60. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.
Hedge Funds Weigh In On Moderna
Institutional investors have recently bought and sold shares of the stock. Cim Investment Management Inc. lifted its holdings in Moderna by 4.2% during the 1st quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock valued at $329,000 after buying an additional 86 shares in the last quarter. Cetera Advisor Networks LLC lifted its stake in shares of Moderna by 0.5% in the 4th quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock valued at $3,088,000 after purchasing an additional 87 shares during the period. Ancora Advisors LLC raised its position in Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after acquiring an additional 96 shares during the period. Sunbelt Securities Inc. raised its position in Moderna by 7.5% during the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after acquiring an additional 100 shares during the period. Finally, Allworth Financial LP raised its position in Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after acquiring an additional 101 shares during the period. 64.51% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Moderna
In other Moderna news, President Stephen Hoge sold 45,000 shares of the company’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $100.01, for a total value of $4,500,450.00. Following the sale, the president now owns 1,531,063 shares in the company, valued at $153,121,610.63. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, President Stephen Hoge sold 45,000 shares of the stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $100.01, for a total transaction of $4,500,450.00. Following the sale, the president now owns 1,531,063 shares in the company, valued at $153,121,610.63. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 647 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders have sold 110,021 shares of company stock worth $11,048,392 over the last 90 days. 15.70% of the stock is owned by company insiders.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
Featured Stories
Receive News & Ratings for Moderna Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moderna and related companies with MarketBeat.com’s FREE daily email newsletter.
